Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2No longer available 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Cholangiocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 9pembrolizumab 7Specimen Handling 7Biopsy 7Leucovorin 5Gemcitabine 5Cisplatin 5durvalumab 4Oxaliplatin 4Fluorouracil 4Capecitabine 4Paclitaxel 3Nivolumab 3Irinotecan 3Carboplatin 3tislelizumab 2olaparib 2fludarabine 2atezolizumab 2Trastuzumab 2Taxes 2Radiation Dose Hypofractionation 2Radiation 2Ipilimumab 2Fluorodeoxyglucose F18 2Cyclophosphamide 2zimberelimab 1varlilumab 1tucatinib 1tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Cholangiocarcinoma × derazantinib × Clear all
NCT05174650 2025-12-05

Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Active not recruiting
27 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡